President Donald Trump today signed an executive order on healthcare. The order will allow businesses to form associations that will have the ability to purchase health coverage from across state lines.
President Donald Trump today signed an executive order on healthcare. The order will allow businesses to form associations that will have the ability to purchase health coverage from across state lines.
Trump said that the ability to purchase such plans would be “Very, very powerful for our nation and very good for a lot of people.” The order also includes provisions for the creation of health plans that will provide short-term, limited-duration coverage, and for exploration of how employers might use health reimbursement arrangements, which are plans that reimburse employees for medical expense paid for out of pocket.
Senator Rand Paul (R-Kentucky) said that “what I believe is the biggest free market reform of healthcare in a generation” that would “…allow millions of people to get insurance across state lines and at an inexpensive price.” Vice President Mike Pence also praised the executive order, saying that it was a “Critical step to lower the cost of health insurance for working Americans.”
While today’s executive order may not be the full repeal of the Affordable Care Act (ACA) that Republicans have promised their supporters, Trump made it clear that today’s effort was part of a larger push to overhaul healthcare: “I just keep hearing repeal, replace; repeal, replace. Well, we’re starting that process,” he said. “I believe we have the votes to do block grants” at a later time, he went on, apparently referring to a plan similar to the one proposed in the Graham-Cassidy healthcare reform bill that recently failed to garner enough support to move to a Senate vote.
Trump also suggested that the ACA individual market would continue to lose participation from insurers, predicting that half of all counties in the nation would have only 1 insurer participating in the ACA health insurance exchanges, and that others would have none. Allowing associations to purchase insurance plans across states would mean that “they will have so many options,” and that competition among plans would be “staggering.”
The president also indicated that the coming months would see his administration taking further measures related to healthcare and to the economy at large. These measures, he promised, would include “massive” tax cuts.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.